Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV002294715 | SCV002587698 | uncertain significance | Atypical hemolytic-uremic syndrome | 2020-03-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003774992 | SCV004623545 | uncertain significance | not provided | 2024-01-02 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 697 of the CFH protein (p.Leu697Phe). This variant is present in population databases (rs201961184, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with CFH-related conditions. ClinVar contains an entry for this variant (Variation ID: 1712460). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004047634 | SCV004923719 | uncertain significance | Inborn genetic diseases | 2023-11-20 | criteria provided, single submitter | clinical testing | The c.2089C>T (p.L697F) alteration is located in exon 14 (coding exon 14) of the CFH gene. This alteration results from a C to T substitution at nucleotide position 2089, causing the leucine (L) at amino acid position 697 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005002821 | SCV005630065 | uncertain significance | Basal laminar drusen; Factor H deficiency; Hemolytic uremic syndrome, atypical, susceptibility to, 1; Age related macular degeneration 4 | 2024-01-24 | criteria provided, single submitter | clinical testing |